TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...
Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...
Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to induce electrical currents in localized regions of the prefrontal cortex. Real-world ...
Patient Receives Depression Treatment Using neurocare’s Apollo TMS System A patient undergoing Transcranial Magnetic Stimulation (TMS) therapy for depression with neurocare’s Apollo TMS System in a ...
83% of patients who complete Transcranial Magnetic Stimulation treatment experience measurable relief and 62% experience full remission of depression symptoms The expanded label positions Neuronetics' ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
Device-based neuromodulation therapies may offer a viable alternative for patients with depression who do not achieve adequate response to SSRIs.
An advanced version of a procedure using magnetic fields to stimulate brain nerve cells in treating depression was significantly effective for 85% of active military and veterans suffering from combat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results